HMAs in combination with immune checkpoint inhibitors were widely used.607 CD47 was a macrophage checkpoint and can be targeted for AML and MDS,608 and its inhibitor in combination with azacitidine had increased efficacy of AML and higher-risk MDS, especially in patients with TP53 mutation.609 T-cell immunoglobulin domain and mucin domain-3 (TIM-3) was a T-cell immune checkpoint, and highly expressed in LSCs. Here, TP53 is linked to myelodysplastic syndrome.